ASX healthcare tech company, OneView (ASX:ONE), is looking for ways to further strengthen investor awareness, entering into an 18-month deal with investment research company, StocksDigital.

StocksDigital is a network of research and investment platforms that lets readers to co-invest in the stocks it covers.

The deal will see StocksDigital share its research, commentary and investment thesis on OneView stock, with the aim to attract potential investor interest.

The service provided by StocksDigital, which is valued at $375,000, will be paid in 6.5 million of OneView’s CDIs (CHESS depository interests).

In addition, StocksDigital has agreed to invest $1,000,000 in OneView for 16,666,666 CDIs, equating to an issue price of $0.06 per security. CDIs are instruments traded on the ASX that allow non-Australian companies to list their shares on the exchange.

OneView’s share price has today rocketed by over 100 per cent to 17c on the news.

Why the deal is good for OneView

The company said the agreement is timely and will give OneView the market exposure it needs to support the global launch of its OneView Cloud for Enterprise product in the US and Australia.

OneView Cloud is a platform that helps healthcare workers conduct their tele-health work caring for COVID-19 patients. The technology is installed on a monitor in the patient’s room, and provides virtual rounding as well as virtual visitors capabilities.

The research coverage provided by StocksDigital will also be important for a small cap like OneView, as small caps usually lack the formal research coverage necessary to attract investors.

StocksDigital itself is a research and investment company,  providing its readers with research information who then co-invest alongside them.  This is done through its investor focused websites, including, and According to the company’s website, it has over 3 million yearly readers, 56 per cent of whom have co-invested with the company.

What’s next?

The CDI allotment to StocksDigital will be subject to shareholders’ approval at an EGM slotted for 15th April. The company said that CDI holders with over 40 per cent holdings have advised that they will vote in favour.

For its full year FY20 results, OneView reported an operating EBITDA loss of EUR 6.2 million, an improvement of the EUR 15.3 million loss it incurred a year earlier.

The company said COVID-19 had prevented access to hospital sites last year, delaying installation and go-lives of its product launches. It expects this to normalise in 2021.

The share price last experienced a surge in February, when it rose by over 90 per cent after announcing a distribution deal with Samsung.


OneView share price chart: